Member Info for Indie07

They shave plates a blinder with that RNS. Put the brakes on to pause and releases the RNS we’ve been waiting for. DYOR
None of this makes sense

..

:( :( :(

This is great news, hopefully will see the RNS here

That’s very upbeat

So far

Pushing through to gap
5.60 paid

Off…

Incoming

.

Bid on the increase

Thank you for your counselling. Lollllll

Check the company website. FDA fast track

The Scientific Advice meeting with the European Medicines Evaluation Agency (EMEA) was held; the recommendations were very similar to those in the FDA’s ‘End Of Phase 2’ responses. Recommendations were incorporated into the Phase III pivotal programme
The Japanese equivalent authorities (PMDA) have agreed to the initiation of clinical trials in Japan
The FDA has granted Lupuzor™ the approval to start Phase III with a Special Protocol Assessment (SPA)
The FDA has granted Lupuzor™ Fast Track designation

Corporate deals involving Lupuzor™

ImmuPharma entered into a corporate deal with Cephalon, Inc. in November 2008 whereby Cephalon licensed worldwide the exclusive rights to Lupuzor™. Due to the acquisition of Cephalon by Teva on October 14, 2011, ImmuPharma regained all rights to Lupuzor™ worldwide and has initiated discussions with other pharmaceutical companies for a new corporate deal.

A Phase IIb clinical trial started dosing of patients in February 2008 in Europe and Latin America, comparing Lupuzor™ to placebo in patients with systemic lupus erythematosus and an interim analysis has demonstrated statistically significant superiority of Lupuzor™ over placebo. The interim analysis was performed and reviewed by an independent Data Monitoring Committee according to ICH guidelines. This analysis was conducted after 125 randomised patients had completed the 12-week treatment period, half of them having also completed the additional 12-week follow-up (week 24).

Lupus (or Systemic Lupus Erythematosus) is a chronic, potentially life-threatening autoimmune disease. An estimated 1.4 million people are diagnosed in the 7
Can be answered …

major world markets (the USA, Japan, Germany,
France, Spain, the UK and Italy). Lupus is an inflammatory disease, which attacks multiple organs such as the skin, joints, kidneys, blood cells, heart and lungs. There is currently no cure.

Lupuzor™ is a potential treatment for lupus. It has been given the 'Gold Standard' approval by the US FDA for its Phase III programme with a Sprecial Protocol Assessment (SPA) and fast track designation. Lupuzor™ has now commenced its pivotal Phase III trial. ImmuPharma holds all worldwide rights in this lead compound.

DYOR, I’m still in the red with this one, but it’s a tight hold now

Hilarious regarding a drop to 5pm

This is hilarious, really funny